aluates Reports

$ 0.0

Automative

Global Next-Generation Breast Cancer Diagnostic and Screening Market Research Report 2025

Published Date: June 2025

Report Code: QYRE-Auto-6P8367

Global Next Generation Breast Cancer Diagnostic and Screening Market Insights Forecast to 2028

BUY CHAPTERS

Global Next-Generation Breast Cancer Diagnostic and Screening Market Research Report 2025

Code: QYRE-Auto-6P8367

Report

June 2025

Pages:81

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Abbott Laboratories

Agendia

Agilent Technologies

Ambry Genetics

Biocept

Biotheranostics

CENTOGENE

Danaher Corporation

Exact Sciences Corporation

Roche Holding AG

Fulgent Genetics

Illumina Inc

Invitae

Lucence Diagnostics Pte. Ltd.

Myriad Genetics

Next-Generation Breast Cancer Diagnostic and Screening Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Next-Generation Breast Cancer Diagnostic and Screening Market

The global market for Next-Generation Breast Cancer Diagnostic and Screening was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Next-Generation Breast Cancer Diagnostic and Screening, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Breast Cancer Diagnostic and Screening.

The Next-Generation Breast Cancer Diagnostic and Screening market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Next-Generation Breast Cancer Diagnostic and Screening market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Next-Generation Breast Cancer Diagnostic and Screening companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Next-Generation Breast Cancer Diagnostic and Screening Market Report

Report Metric	Details
Report Name	Next-Generation Breast Cancer Diagnostic and Screening Market
CAGR	5%
Segment by Type	Real-Time PCR (q-PCR) Immunohistochemistry (IHC) Next-Generation Sequencing (NGS) Fluorescent In-Situ Hybridization (FISH)
Segment by Application	Hospital-associated Labs Cancer Research Institutes Diagnostic Centers
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics, Biocept, Biotheranostics, Centogene, Danaher Corporation, EXACT Sciences Corporation, Roche Holding AG, Fulgent Genetics, Illumina, Invitae, Lucence Diagnostics Pte Ltd, Myriad Genetics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next-Generation Breast Cancer Diagnostic and Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Next-Generation Breast Cancer Diagnostic and Screening Market report?

Ans: The main players in the Next-Generation Breast Cancer Diagnostic and Screening Market are Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics, Biocept, Biotheranostics, Centogene, Danaher Corporation, EXACT Sciences Corporation, Roche Holding AG, Fulgent Genetics, Illumina, Invitae, Lucence Diagnostics Pte Ltd, Myriad Genetics

What are the Application segmentation covered in the Next-Generation Breast Cancer Diagnostic and Screening Market report?

Ans: The Applications covered in the Next-Generation Breast Cancer Diagnostic and Screening Market report are Hospital-associated Labs, Cancer Research Institutes, Diagnostic Centers

What are the Type segmentation covered in the Next-Generation Breast Cancer Diagnostic and Screening Market report?

Ans: The Types covered in the Next-Generation Breast Cancer Diagnostic and Screening Market report are Real-Time PCR (q-PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH)

Recommended Reports

Cancer Diagnostics

Breast Cancer Therapy

Precision Oncology Markets

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Real-Time PCR (q-PCR)

1.2.3 Immunohistochemistry (IHC)

1.2.4 Next-Generation Sequencing (NGS)

1.2.5 Fluorescent In-Situ Hybridization (FISH)

1.3 Market by Application

1.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital-associated Labs

1.3.3 Cancer Research Institutes

1.3.4 Diagnostic Centers

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Perspective (2020-2031)

2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Growth Trends by Region

2.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Region (2020-2025)

2.2.3 Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2026-2031)

2.3 Next-Generation Breast Cancer Diagnostic and Screening Market Dynamics

2.3.1 Next-Generation Breast Cancer Diagnostic and Screening Industry Trends

2.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers

2.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market Challenges

2.3.4 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue

3.1.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue (2020-2025)

3.1.2 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Players (2020-2025)

3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Next-Generation Breast Cancer Diagnostic and Screening Revenue

3.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio

3.4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2024

3.5 Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening Head office and Area Served

3.6 Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Product and Application

3.7 Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Type

4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Type (2020-2025)

4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2026-2031)

5 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Application

5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Application (2020-2025)

5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)

6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)

6.4 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)

7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)

7.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)

8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2020-2025)

8.4 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)

9.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)

9.4 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)

10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)

10.4 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Abbott Laboratories

11.1.1 Abbott Laboratories Company Details

11.1.2 Abbott Laboratories Business Overview

11.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.1.4 Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.1.5 Abbott Laboratories Recent Development

11.2 Agendia

11.2.1 Agendia Company Details

11.2.2 Agendia Business Overview

11.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.2.4 Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.2.5 Agendia Recent Development

11.3 Agilent Technologies

11.3.1 Agilent Technologies Company Details

11.3.2 Agilent Technologies Business Overview

11.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.3.4 Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.3.5 Agilent Technologies Recent Development

11.4 Ambry Genetics

11.4.1 Ambry Genetics Company Details

11.4.2 Ambry Genetics Business Overview

11.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.4.4 Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.4.5 Ambry Genetics Recent Development

11.5 Biocept

11.5.1 Biocept Company Details

11.5.2 Biocept Business Overview

11.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.5.4 Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.5.5 Biocept Recent Development

11.6 Biotheranostics

11.6.1 Biotheranostics Company Details

11.6.2 Biotheranostics Business Overview

11.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.6.4 Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.6.5 Biotheranostics Recent Development

11.7 Centogene

11.7.1 Centogene Company Details

11.7.2 Centogene Business Overview

11.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.7.4 Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.7.5 Centogene Recent Development

11.8 Danaher Corporation

11.8.1 Danaher Corporation Company Details

11.8.2 Danaher Corporation Business Overview

11.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.8.4 Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.8.5 Danaher Corporation Recent Development

11.9 EXACT Sciences Corporation

11.9.1 EXACT Sciences Corporation Company Details

11.9.2 EXACT Sciences Corporation Business Overview

11.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.9.4 EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.9.5 EXACT Sciences Corporation Recent Development

11.10 Roche Holding AG

11.10.1 Roche Holding AG Company Details

11.10.2 Roche Holding AG Business Overview

11.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.10.4 Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.10.5 Roche Holding AG Recent Development

11.11 Fulgent Genetics

11.11.1 Fulgent Genetics Company Details

11.11.2 Fulgent Genetics Business Overview

11.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.11.4 Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.11.5 Fulgent Genetics Recent Development

11.12 Illumina

11.12.1 Illumina Company Details

11.12.2 Illumina Business Overview

11.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.12.4 Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.12.5 Illumina Recent Development

11.13 Invitae

11.13.1 Invitae Company Details

11.13.2 Invitae Business Overview

11.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.13.4 Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.13.5 Invitae Recent Development

11.14 Lucence Diagnostics Pte Ltd

11.14.1 Lucence Diagnostics Pte Ltd Company Details

11.14.2 Lucence Diagnostics Pte Ltd Business Overview

11.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.14.4 Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.14.5 Lucence Diagnostics Pte Ltd Recent Development

11.15 Myriad Genetics

11.15.1 Myriad Genetics Company Details

11.15.2 Myriad Genetics Business Overview

11.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.15.4 Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

11.15.5 Myriad Genetics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Abbott Laboratories

Agendia

Agilent Technologies

Ambry Genetics

Biocept

Biotheranostics

CENTOGENE

Danaher Corporation

Exact Sciences Corporation

Roche Holding AG

Fulgent Genetics

Illumina Inc

Invitae

Lucence Diagnostics Pte. Ltd.

Myriad Genetics

List of Tables

Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Real-Time PCR (q-PCR)

Table 3. Key Players of Immunohistochemistry (IHC)

Table 4. Key Players of Next-Generation Sequencing (NGS)

Table 5. Key Players of Fluorescent In-Situ Hybridization (FISH)

Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2020-2025)

Table 10. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2026-2031)

Table 12. Next-Generation Breast Cancer Diagnostic and Screening Market Trends

Table 13. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers

Table 14. Next-Generation Breast Cancer Diagnostic and Screening Market Challenges

Table 15. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints

Table 16. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players (2020-2025)

Table 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2024)

Table 19. Ranking of Global Top Next-Generation Breast Cancer Diagnostic and Screening Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Headquarters and Area Served

Table 22. Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Product and Application

Table 23. Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2020-2025)

Table 27. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2026-2031)

Table 29. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2020-2025)

Table 31. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2026-2031)

Table 33. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)

Table 48. Abbott Laboratories Company Details

Table 49. Abbott Laboratories Business Overview

Table 50. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product

Table 51. Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 52. Abbott Laboratories Recent Development

Table 53. Agendia Company Details

Table 54. Agendia Business Overview

Table 55. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product

Table 56. Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 57. Agendia Recent Development

Table 58. Agilent Technologies Company Details

Table 59. Agilent Technologies Business Overview

Table 60. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product

Table 61. Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 62. Agilent Technologies Recent Development

Table 63. Ambry Genetics Company Details

Table 64. Ambry Genetics Business Overview

Table 65. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product

Table 66. Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 67. Ambry Genetics Recent Development

Table 68. Biocept Company Details

Table 69. Biocept Business Overview

Table 70. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product

Table 71. Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 72. Biocept Recent Development

Table 73. Biotheranostics Company Details

Table 74. Biotheranostics Business Overview

Table 75. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product

Table 76. Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 77. Biotheranostics Recent Development

Table 78. Centogene Company Details

Table 79. Centogene Business Overview

Table 80. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product

Table 81. Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 82. Centogene Recent Development

Table 83. Danaher Corporation Company Details

Table 84. Danaher Corporation Business Overview

Table 85. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product

Table 86. Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 87. Danaher Corporation Recent Development

Table 88. EXACT Sciences Corporation Company Details

Table 89. EXACT Sciences Corporation Business Overview

Table 90. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product

Table 91. EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 92. EXACT Sciences Corporation Recent Development

Table 93. Roche Holding AG Company Details

Table 94. Roche Holding AG Business Overview

Table 95. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product

Table 96. Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 97. Roche Holding AG Recent Development

Table 98. Fulgent Genetics Company Details

Table 99. Fulgent Genetics Business Overview

Table 100. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product

Table 101. Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 102. Fulgent Genetics Recent Development

Table 103. Illumina Company Details

Table 104. Illumina Business Overview

Table 105. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product

Table 106. Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 107. Illumina Recent Development

Table 108. Invitae Company Details

Table 109. Invitae Business Overview

Table 110. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product

Table 111. Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 112. Invitae Recent Development

Table 113. Lucence Diagnostics Pte Ltd Company Details

Table 114. Lucence Diagnostics Pte Ltd Business Overview

Table 115. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product

Table 116. Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 117. Lucence Diagnostics Pte Ltd Recent Development

Table 118. Myriad Genetics Company Details

Table 119. Myriad Genetics Business Overview

Table 120. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product

Table 121. Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)

Table 122. Myriad Genetics Recent Development

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Next-Generation Breast Cancer Diagnostic and Screening Picture

Figure 2. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type: 2024 VS 2031

Figure 4. Real-Time PCR (q-PCR) Features

Figure 5. Immunohistochemistry (IHC) Features

Figure 6. Next-Generation Sequencing (NGS) Features

Figure 7. Fluorescent In-Situ Hybridization (FISH) Features

Figure 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application: 2024 VS 2031

Figure 10. Hospital-associated Labs Case Studies

Figure 11. Cancer Research Institutes Case Studies

Figure 12. Diagnostic Centers Case Studies

Figure 13. Next-Generation Breast Cancer Diagnostic and Screening Report Years Considered

Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region: 2024 VS 2031

Figure 17. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players in 2024

Figure 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2024

Figure 20. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)

Figure 22. United States Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)

Figure 26. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2020-2031)

Figure 34. China Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)

Figure 42. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)

Figure 46. Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Abbott Laboratories Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 50. Agendia Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 51. Agilent Technologies Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 52. Ambry Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 53. Biocept Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 54. Biotheranostics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 55. Centogene Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 56. Danaher Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 57. EXACT Sciences Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 58. Roche Holding AG Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 59. Fulgent Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 60. Illumina Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 61. Invitae Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 62. Lucence Diagnostics Pte Ltd Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 63. Myriad Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novel Cancer Diagnostic Solutions Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Next Generation Gynecological Cancer Diagnostics Market Research Report 2024

AI for Early Cancer Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cancer Diagnostics Service Market Research Report 2025

Precision Cancer Diagnostic Solutions Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Breast Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

AI for Cancer Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Non invasive Cancer Diagnosis Market Research Report 2024

Breast Cancer Generic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Drugs for Breast Cancer Market Research Report 2024

Global Cancer Diagnostic Kit Market Research Report 2024

Global Cancer Tissue Diagnostics Market Research Report 2024

Liver Cancer Diagnostic Tests Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Molecular Diagnosis of Tumors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oncology Based Molecular Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Prostate Cancer Diagnostics and Therapy Market Research Report 2024

Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Next Generation Immunology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gynecological Cancer Diagnostics Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions